(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 January 2013 (31.01.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/016073 A1

(51) International Patent Classification:
A61K 31/4174 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4184 (2006.01)

(21) International Application Number:
PCT/US2012/047064

(22) International Filing Date:
17 July 2012 (17.07.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/510,521 22 July 2011 (22.07.2011) US

(71) Applicant *(for all designated States except US)*: **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, California 92612 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **STAUBLI, Ursula V.** [US/US]; 3019 Mountain View Dr., Laguna Beach, California 92651 (US). **FOSTER, Alan C.** [GB/US]; 5280 Vista Del Dios, San Diego, California 92130 (US). **GIL, Daniel W.** [US/US]; 2541 Point Del Mar, Corona Del Mar, California 92625 (US). **DONELLO, John E.** [US/US]; 34041 Pequito Drive, Dana Point, California 92629 (US).

(74) Agents: **ENE, Doina** et al.; Allergan, Inc., 2525 Dupont Drive, Irvine, California 92612 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]


(54) Title: ALPHA-2 ADRENERGIC MODULATORS FOR TREATING VISUAL DISORDERS MEDIATED BY CENTRAL VISUAL PROJECTIONS FROM THE EYE

(57) Abstract: The present invention relates to a method for treating visual disorders mediated by lateral geniculate nucleus, superior colliculus and the visual cortex by administering to a patient in need of such treatment, compounds acting at the alpha 2 adrenergic receptors.

FIGURE 1

Dose-dependent facilitation of LTP in rat visual cortex by

4-bromo-N-(imidazolidin-2-ylidene)-1H-benzimidazol-5-amine



WO 2013/016073 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*